Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval

February 6, 2018 – Treatment with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved survival versus single-agent vemurafenib in patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to updated findings from the phase III COLUMBUS trial. The combination of encorafenib at 450 mg daily and binimetinib at 45 mg twice daily reduced the risk of death by 39% versus vemurafenib monotherapy (hazard ratio … (leggi tutto)